APOA2 and myeloid sarcoma: Markers for differentiating NMOSD from MS were also identified, including VLDL-3-PL (AUC = 0.791), VLDL-2-FC (AUC = 0.781), VLDL-2-CH (AUC = 0.774), IDL-PL (AUC = 0.772), VLDL-3-FC (AUC = 0.757), and HDL-3-Apo-A2 (AUC = 0.752; Fig. 2).